Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs IRTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRTC Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

IRTC Overall Winner 6-Pillar Tally: AXNX 0 – 6 IRTC Matrix Metrics: AXNX 1 – 9 IRTC

As of Nov 20, 2026, iRhythm Technologies, Inc (IRTC) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas IRTC carries 64.5/100 (BUY) at $94.72 (61.6x Forward P/E, 4.5% operating margin).

  • Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile IRTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs IRTC
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
IRTC NASDAQ Head-to-Head Winner
iRhythm Technologies, Inc
Surgical & Medical Instruments & Apparatus
$94.72
+0.51% 1D
Market Cap $3.2B
TTM Revenue $854M
Forward P/E 61.6x
Beta / 30D Vol 0.35β · 115% Vol
Unified Composite Score
64.5 / 100 BUY
Tech 92.0 Fund 77.0 Flow 68.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 40
RSI-14: 40.1 · SMA20: $107.05 · SMA50: $109.26

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 6 IRTC)

Columns: Metric · AXNX · IRTC
1. Valuation Multiples IRTC
Forward P/E N/M 61.6x
Trailing P/E N/M 56.2x
PEG Ratio N/M N/M
EV / Revenue N/M 4.1x
2. Growth & Scale IRTC
Revenue Growth (YoY) N/A +14.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $854M
Market Cap N/A $3.2B
3. Profitability & Quality IRTC
Gross Margin N/A 71.9%
Operating Margin N/A 4.5%
Net Profit Margin N/A -4.5%
Return on Equity (ROE) N/A -25.8%
4. Balance Sheet & Cash Flow IRTC
Cash Generation (TTM) N/A $7.4M
Cash Flow Margin N/A 0.9%
Net Cash / Leverage N/A ROE $376M Net Debt (4.35x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRTC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 60.0% (16th %ile)
Put/Call OI Skew N/A 0.12x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IRTC
OpEx & R&D Intensity N/A 67.4% of Rev ($576M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (1) vs IRTC (9)
Institutional Metric AXNX IRTC Criterion Row Edge
Market Capitalization
Scale
N/A $3.2B Larger Scale IRTC
Trailing P/E Ratio
Valuation
N/M 56.2x Lower Multiple IRTC
Forward P/E Ratio
Valuation
N/M 61.6x Lower Multiple IRTC
Revenue Growth (YoY)
Growth
N/A +14.9% Higher Growth IRTC
Operating Margin (TTM)
Profitability
N/A 4.5% Higher Margin IRTC
Net Profit Margin
Profitability
N/A -4.5% Higher Margin IRTC
Return on Equity (ROE)
Capital Efficiency
N/A -25.8% Higher ROE IRTC
52-Week Range Position
Momentum
50% ($0–$1) 11% ($83–$192) Stronger Trend AXNX
Beta / 30D Volatility
Risk Regime
N/A 0.35β · 115% Vol Lower Realized Risk IRTC
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 64.5 / 100 (BUY) Higher Composite IRTC
Trailing 12M Revenue (USD)
Operating Scale
N/A $854M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 71.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $7.4M ($376M Net Debt (4.35x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRTC +5.71 pp
AXNX: -26.54% · IRTC: -20.83%
3M Horizon AXNX +28.98 pp
AXNX: +16.92% · IRTC: -12.06%
6M Horizon AXNX +28.98 pp
AXNX: +16.92% · IRTC: -12.06%
1Y Horizon AXNX +28.98 pp
AXNX: +16.92% · IRTC: -12.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs IRTC. Trailing 12-month operating profitability (AXNX N/A vs IRTC 4.5%) and valuation multiples (AXNX N/M vs IRTC 61.6x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
IRTC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$854M
Gross Margin71.9%
Op. Margin4.5%
ROE / Fwd P/E-25.8% · 61.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRTC BREAKDOWN
12d in phase · OBV NEUTRAL
Current IV 60.0%
IV Percentile 16th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IRTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IRTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.2B market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 67.4% of Rev ($576M)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs IRTC Key Questions & Quantitative Answers

As of Nov 20, 2026, iRhythm Technologies, Inc (IRTC) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas IRTC carries 64.5/100 (BUY) at $94.72 (61.6x Forward P/E, 4.5% operating margin). Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile IRTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRTC leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IRTC at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $854M TTM revenue (71.9% gross margin, 4.5% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $854M for IRTC. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 67.4% of Rev ($576M) (0 disclosures) for IRTC.

IRTC screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IRTC trades at 61.6x Forward P/E, 56.2x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (0.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus IRTC (-25.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, IRTC carries 60.0% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.35β · 115% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.